Ovid Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Ovid Therapeutics

11/05/2022 13:00

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 21 cents per share.
    * Revenue fell 99.3% to $1.45 million from a year ago; 
analysts
expected zero. 
    * Ovid Therapeutics Inc's reported EPS for the quarter was a
loss
of 23 cents​.
    * The mean earnings estimate of analysts had fallen by
about 27.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Ovid Therapeutics Inc shares had fallen by 11.5% this
quarter and lost 13.4% so far this year.
    * The company reported a quarterly loss of $16.11 million.
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 11 at 11:59 a.m.  ​All
figures in US dollars unless otherwise stated